Prostate Cancer: 177 Lu-PSMA (Pluvicto)

Journal of Nuclear Medicine Technology 2026

View at publisher
Authors: Mary Beth Farrell, Kathy S. Thomas, Eleanor S. Mantel, Jessica Settle
DOI: 10.2967/jnmt.126.272485
Cited by: 1
References: 1

Abstract

177Lu-PSMA-617 (brand name Pluvicto), is a prostate-specific membrane antigen (PSMA) targeted ligand therapy. PSMA is overexpressed in most prostate adenocarcinomas and this property can be exploited therapeutically. It is prescribed for patients diagnosed with hormone-resistant metastatic prostate

Fields of Study & Subjects

Prostate Cancer Treatment and Research Radiopharmaceutical Chemistry and Applications Chemical Reactions and Isotopes

Publication details

Journal / source
Journal of Nuclear Medicine Technology
Publisher
Society of Nuclear Medicine
Volume
54
Issue
2
Pages
166–167
Publication date
31 March 2026
Language
EN